V325
Regimen
- Experimental
- docetaxel 75 + cisplatin 75 d1 + 5FU 750/d d1-5 Q3W (DCF)
- Control
- cisplatin 100 d1 + 5FU 1000/d d1-5 Q4W (CF)
Population
Advanced gastric cancer receiving first-line therapy
Key finding
mOS 9.2 vs 8.6 mo (HR 0.77, p=0.02); TTP 5.6 vs 3.7 mo; ORR 37% vs 25%; 2-yr OS 18% vs 9%; grade 3-4 neutropenia 82%
Source: PMID 17075117
Timeline
Guideline citations
- NCCN GASTRIC (p.38)
- CSCO GASTRIC 2025 (p.110)⚠️ OCR source